Pulmonary arterial hypertension: Basis of sex differences in incidence and treatment response

British Journal of Pharmacology

Volumn 171, Issue 3, 2014, Pages 567-579

  Mair, K M ^a   Johansen, A K Z ^a   Wright, A F ^a   Wallace, E ^a   Maclean, M R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

oestrogen; pulmonary arterial hypertension; serotonin; sex hormones; testosterone; vascular remodelling

Indexed keywords

ANASTROZOLE; ANTICOAGULANT AGENT; AROMATASE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM CHANNEL BLOCKING AGENT; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; DEXFENFLURAMINE; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ILOPROST; NIFEDIPINE; OXYGEN; PROSTACYCLIN; PROTEIN S100B; SEX HORMONE; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ADULT; AGED; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG HALF LIFE; FEMALE; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; INJECTION SITE REACTION; LUNG ARTERY PRESSURE; LUNG CIRCULATION; MALE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; TREATMENT RESPONSE;

OESTROGEN; PULMONARY ARTERIAL HYPERTENSION; SEROTONIN; SEX HORMONES; TESTOSTERONE; VASCULAR REMODELLING;

ANDROGENS; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; LUNG; MALE; MODELS, BIOLOGICAL; PULMONARY CIRCULATION; RECEPTORS, ESTROGEN; SEX CHARACTERISTICS; VASCULAR RESISTANCE;

EID: 84892420254     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12281     Document Type: Review

References (123)

1. Achar S, Rostamian A, Narayan SM, (2010). Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 106: 893-901.
2. Ahn BH, Park HK, Cho HG, Lee HA, Lee YM, Yang EK, et al. (2003). Estrogen and enalapril attenuate the development of right ventricular hypertrophy induced by monocrotaline in ovariectomized rats. J Korean Med Sci 18: 641-648.
3. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. (2009). Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir 34: 1093-1099.
4. Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, et al. (2012). BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 3: 6.
5. Badawi AF, Cavalieri EL, Rogan EG, (2001). Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 50: 1001-1003.
6. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. (2010). Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137: 376-387.
7. Barrett-Connor E, Goodman-Gruen D, (1995). The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci 774: 259-270.
8. Barrett-Connor E, Khaw KT, Yen SS, (1986). A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315: 1519-1524.
9. Baulieu EE, (2002). Androgens and aging men. Mol Cell Endocrinol 198: 41-49.
10. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122: 164-172.
11. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD, (2012). An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142: 448-456.
12. Bonnet S, Dumas-de-La-Roque E, Begueret H, Marthan R, Fayon M, Dos Santos P, et al. (2003). Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A 100: 9488-9493.
13. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, et al. (2009). Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 120: 1231-1240.
14. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, et al. (1997). Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33: 196-200.
15. Channick RN, Voswinckel R, Rubin LJ, (2012). Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther 6: 19-28.
16. Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, et al. (2004). Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59: 446-448.
17. Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, et al. (2009). Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 13: 1-320.
18. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB, (2004). Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32: 840-847.
19. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. (1992). An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75.
20. Ciolino H, MacDonald C, Memon O, Dankwah M, Yeh GC, (2003). Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo. Int J Cancer 105: 321-325.
21. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, et al. (2011). A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 1171-1182.
22. Ciuclan L, Hussey MJ, Burton V, Good R, Duggan N, Beach S, et al. (2013). Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression. Am J Respir Crit Care Med 187: 78-89.
23. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, et al. (1999). Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411-419.
24. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. (1991). Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
25. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ, (2001). Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281: H1720-H1727.
26. Dempsie Y, MacRitchie NA, Morecroft I, Nilsen M, Loughlin L, MacLean MR, (2009). The effects of gender on the development of dexfenfluramine-induced pulmonary arterial hypertension in mice. Am J Respir Crit Care Med 179: A1808.
27. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, et al. (2011). Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res 12: 159.
28. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. (2000). Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737-744.
29. Dessouroux A, Akwa Y, Baulieu EE, (2008). DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension. J Steroid Biochem Mol Biol 109: 81-89.
30. Dubey RK, Oparil S, Imthurn B, Jackson EK, (2002). Sex hormones and hypertension. Cardiovasc Res 53: 688-708.
31. Dumas de la Roque E, Savineau JP, Bonnet S, (2010). Dehydroepiandrosterone: a new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 126: 186-199.
32. Dwyer N, Kilpatrick D, (2011). Bosentan for the treatment of adult pulmonary hypertension. Future Cardiol 7: 19-37.
33. English KM, Jones RD, Jones TH, Morice AH, Channer KS, (2001). Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 33: 645-652.
34. Farhat MY, Chen MF, Bhatti T, Iqbal A, Cathapermal S, Ramwell PW, (1993). Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol 110: 719-723.
35. Farrukh IS, Peng W, Orlinska U, Hoidal JR, (1998). Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener. Am J Physiol 274: L186-L195.
36. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, (2000). Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660.
37. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. (2011). The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 139: 128-137.
38. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, et al. (2012). Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141: 20-26.
39. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. (2009a). Tadalafil therapy for pulmonary arterial hypertension. Circulation 119: 2894-2903.
40. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. (2009b). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537.
41. Galie N, Negro L, Simonneau G, (2009c). The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 18: 148-153.
42. Giaid A, Saleh D, (1995). Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221.
43. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-1739.
44. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, et al. (2012). A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 302: L977-L991.
45. Gupte SA, Li KX, Okada T, Sato K, Oka M, (2002). Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium channels. J Pharmacol Exp Ther 301: 299-305.
46. Hall J, Jones RD, Jones TH, Channer KS, Peers C, (2006). Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology 147: 2675-2680.
47. Hampl V, Bibova J, Povysilova V, Herget J, (2003). Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J 21: 862-865.
48. Hayward CS, Webb CM, Collins P, (2001). Effect of sex hormones on cardiac mass. Lancet 357: 1354-1356.
49. Hemnes AR, Maynard KB, Champion HC, Gleaves L, Penner N, West J, et al. (2012). Testosterone negatively regulates right ventricular load stress responses in mice. Pulm Circ 2: 352-358.
50. Homma N, Nagaoka T, Morio Y, Ota H, Gebb SA, Karoor V, et al. (2007). Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 50: 697-702.
51. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. (2006). Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173: 1023-1030.
52. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. (2010a). Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-163.
53. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jais X, et al. (2010b). Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 36: 549-555.
54. Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS, (2002). Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol 39: 814-823.
55. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, et al. (2008). Clinical risk factors for portopulmonary hypertension. Hepatology 48: 196-203.
56. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Weil B, et al. (2008). Exogenous estrogen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock 30: 660-667.
57. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, et al. (2012). 17beta-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 185: 965-980.
58. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81-84.
59. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT, (2003). Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144: 3382-3398.
60. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. (2012). Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 186: 790-796.
61. Liu PY, Death AK, Handelsman DJ, (2003). Androgens and cardiovascular disease. Endocr Rev 24: 313-340.
62. Lizotte E, Grandy SA, Tremblay A, Allen BG, Fiset C, (2009). Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. Cell Physiol Biochem 23: 75-86.
63. Maclean MR, Dempsie Y, (2010). The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol 661: 309-322.
64. Masi AT, (1976). Editorial: pulmonary hypertension and oral contraceptive usage. Chest 69: 451-453.
65. Matori H, Umar S, Nadadur RD, Sharma S, Partow-Navid R, Afkhami M, et al. (2012). Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension 60: 425-430.
66. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, et al. (2009). Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 135: 122-129.
67. Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Janne OA, (2010). Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317: 14-24.
68. Mikstacka R, Baer-Dubowska W, Wieczorek M, Sobiak S, (2008). Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Mol Nutr Food Res 52 (Suppl. 1): S77-S83.
69. Miyauchi T, Yanagisawa M, Iida K, Ajisaka R, Suzuki N, Fujino M, et al. (1992). Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J 123: 1092-1093.
70. Morani A, Barros RP, Imamov O, Hultenby K, Arner A, Warner M, et al. (2006). Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci U S A 103: 7165-7169.
71. Murray F, Maclean MR, Insel PA, (2011). Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. Handb Exp Pharmacol 204: 279-305.
72. Nadadur RD, Umar S, Wong G, Eghbali M, Iorga A, Matori H, et al. (2012). Reverse right ventricular structural and extracellular matrix remodeling by estrogen in severe pulmonary hypertension. J Appl Physiol 113: 149-158.
73. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA 3rd, et al. (2001). Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345: 319-324.
74. Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Golembeski SM, et al. (2007). Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res 74: 377-387.
75. Olschewski H, (2009). Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 18: 29-34.
76. Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al. (2009). Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54: 1971-1981.
77. Parker CR Jr, (1999). Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids 64: 640-647.
78. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S, (2011). Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 301: H1798-H1809.
79. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ, (1993). Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118: 429-432.
80. Rabinovitch M, (2008). Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379.
81. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L, (1981). Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 240: H62-H72.
82. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, et al. (2010). Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 298: H1235-H1248.
83. Resta TC, Kanagy NL, Walker BR, (2001). Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol 280: L88-L97.
84. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. (1987). Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107: 216-223.
85. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al. (2009). Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 179: 835-842.
86. Rowell KO, Hall J, Pugh PJ, Jones TH, Channer KS, Jones RD, (2009). Testosterone acts as an efficacious vasodilator in isolated human pulmonary arteries and veins: evidence for a biphasic effect at physiological and supra-physiological concentrations. J Endocrinol Invest 32: 718-723.
87. Rubin LJ, (2012). Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci 91: 517-521.
88. Rubtsov AV, Rubtsova K, Kappler JW, Marrack P, (2010). Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 9: 494-498.
89. Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide M-V, Aguirre C, (2012). Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 12: 410-415.
90. Scragg JL, Jones RD, Channer KS, Jones TH, Peers C, (2004). Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun 318: 503-506.
91. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ, (2012). Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 141: 363-373.
92. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. (2009). Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-S54.
93. Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, et al. (2005). Estrogen-the good, the bad, and the unexpected. Endocr Rev 26: 322-330.
94. Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS, Jones RD, (2008). Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Manag 4: 1459-1466.
95. Sweeney L, Voelkel NF, (2009). Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur J Med Res 14: 433-442.
96. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. (2012). Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): a Randomized Controlled Trial. Chest 142: 1383-1390.
97. Teoh H, Quan A, Leung SW, Man RY, (2000). Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. Br J Pharmacol 129: 1301-1308.
98. Tep-areenan P, Kendall DA, Randall MD, (2002). Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 135: 735-740.
99. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. (2000). Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 37: 741-745.
100. Thorne S, Nelson-Piercy C, MacGregor A, Gibbs S, Crowhurst J, Panay N, et al. (2006). Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care 32: 75-81.
101. Thum T, Borlak J, (2002). Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16: 1537-1549.
102. Tofovic SP, Rafikova O, Champion H, Schneider F, (2012). Estrogens exacerbate development of occlusive pulmonary arterial hypertension and formation of plexiform lesions. Am J Respir Crit Care Med 185: A6803.
103. Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G, (2008). 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol 48: 174-183.
104. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. (2001). Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345: 325-334.
105. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. (1999). Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932.
106. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, et al. (2011). Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med 184: 715-723.
107. Umar S, Rabinovitch M, Eghbali M, (2012). Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Am J Respir Crit Care Med 186: 125-131.
108. Vander AJ, Moore LG, Brewer G, Menon KM, England BG, (1978). Effects of high altitude on plasma concentrations of testosterone and pituitary gonadotropins in man. Aviat Space Environ Med 49: 356-357.
109. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, et al. (2011). Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med 183: 659-667.
110. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, et al. (2006). Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 152: 521-526.
111. Weiss BM, Zemp L, Seifert B, Hess OM, (1998). Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 31: 1650-1657.
112. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR, (2011a). The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 90: 373-382.
113. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, et al. (2011b). Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics 43: 417-437.
114. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, et al. (2012). Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation 126: 1087-1098.
115. Williams JR, (2000). The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging. Lipids 35: 325-331.
116. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, et al. (2002). Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 87: 176-181.
117. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, et al. (2004). Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 89: 4708-4715.
118. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA, (2001). Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol 25: 104-110.
119. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, et al. (2010). Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res 11: 182.
120. Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei HY, et al. (2012). Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, PGI2 and ET-1 pathways. Eur Respir J 41: 1116-1125.
121. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P, (1995). Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91: 1154-1160.
122. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR, (2006). Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 147: 4132-4150.
123. Zhu D, Ran Y, (2006). Role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in hypoxia-induced pulmonary hypertension. J Physiol Sci 62: 163-172.